Dr Luis A Bauzo, MD in Bomoseen, VT - Pediatrics

Dr Luis A Bauzo, MD is a Pediatrics physician based in Bomoseen, Vermont. Dr Luis A Bauzo is licensed to practice in Vermont (license number 042-0011290) and his current practice location is 275 Route 30 N, Bomoseen, Vermont. He can be reached at his office (for appointments etc.) via phone at (802) 468-5641.

NPI number for Dr Luis A Bauzo is 1598930844 and his current mailing address is 71 Allen St, Ste 101, Rutland, Vermont. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1598930844.

Contact Information

	Dr Luis A Bauzo, MD
	275 Route 30 N, Bomoseen, VT 05732-9647
	(802) 468-5641
	(802) 468-2923

Physician's Profile

Full Name	Dr Luis A Bauzo
Gender	Male
Speciality	Pediatrics
Location	275 Route 30 N, Bomoseen, Vermont
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1598930844
Provider Enumeration Date: 04/28/2008
Last Update Date: 11/18/2016

Medical Identifiers

Medical identifiers for Dr Luis A Bauzo such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1598930844	NPI	-	NPPES
03890448	Medicaid	NY
1015069	Medicaid	VT

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208000000X	Pediatrics	042-0011290 (Vermont)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Luis A Bauzo is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Luis A Bauzo, MD 71 Allen St, Ste 101, Rutland, VT 05701-4570 Ph: (802) 772-4414	Dr Luis A Bauzo, MD 275 Route 30 N, Bomoseen, VT 05732-9647 Ph: (802) 468-5641

News Archive

Obama administration regulatory review won't include health law rules

An official from the Department of Health and Human Services told a House oversight subcommittee that the health law's regulations are too new for a second look. However, some Republican members of the panel disagreed, saying that the waivers that have been granted are reason enough for such examination.

ASU Biodesign Institute hosts international research consortium on early detection of lung cancer

To address the latest issues on the early detection of lung cancer, the Biodesign Institute at Arizona State University will host an international research consortium in Scottsdale, Ariz., Feb. 25-26.

Results of Phase IIb dose range finding of oglemilast in chronic obstructive pulmonary disease announced

Forest Laboratories, Inc. (NYSE: FRX) and Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) today announced top-line results from a Phase IIb dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). Once-daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.

Researchers investigate familial prosopagnosia to recognize faces

In our dynamic 3D world, we can encounter a familiar face from any angle and still recognize that face with ease, even if the person has, for example, changed his hair style. This is because our brain has used the 2D snapshots perceived by our eyes (like a camera) to build and store a 3D mental representation of the face, which is resilient to such changes.

Dr Luis A Bauzo, MD - Pediatrics in Bomoseen, VT